Return to List

Study Summary
No. 2010-0788:.......Leukemia......Elias Jabbour......Leukemia
.
Study Summary Title
Study Summary
Number:		2010-0788
Study Title:Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
.
Physician New Patient Referral
Name:Elias JabbourPatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:LeukemiaReferring MD
Call:		800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-792-4764
Contact us about clinical trials
.
General Information
Disease Group:LeukemiaSupported By:N/A
Phase of Study:Phase IIReturn
Visit:
Treatment
Agents:		Clofarabine
Cytarabine
Fludarabine
Idarubicin		Home Care:
Treatment Loc:Only at MDACC
Estimated
Length of Stay
in Houston:
Description/
Intervention:		The goal of this clinical research study is to learn if the combination of
clofarabine, idarubicin, and cytarabine, or the combination of fludarabine,
idarubicin, and cytarabine can help control AML and MDS. The safety of these
study drug combinations will also be studied.
.
Study Objectives / Outcomes
Phase I
Primary:
Determine the MTD of clofarabine to be used in portion II of the study.
Phase II
Primary:
Compare the response rates of two different regimens CIA versus FLAI
Secondary:
Evaluate the durability of response, the overall and event-free survival rates, and the safety profile of 2 different regimens.
.
Study Status Information
Study Activation / Registration Date:
IRB Review and Approval Date:02/02/2011
Study Type:Phase Ii Or Phase I/Ii
Recruitment Status:Open
Projected Accrual:N/A
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.
Inclusion Criteria:1) Sign an IRB-approved informed consent document.

2) Age 18 to 60. Patients above the age of 60 only with PI approval

3) Diagnosis of newly diagnosed AML [other than acute promyelocytic leukemia (APL)] or high-risk (intermediate-2 or high by IPSS or > 10% blasts, including CMML) MDS. Prior therapy with hydrea and the use of a single or a two day dose of cytarabine (up to 3 g/m2) for emergency use up to 24 hours prior to start of study therapy is allowed. Prior therapy for MDS or other AHD is not allowed.

4) ECOG performance status of </= 3 at study entry.

5) Organ function as defined below (unless due to leukemia): Serum creatinine </= 3 mg/dL Total bilirubin </= 2.5 mg/dL , ALT (SGPT) </= 3 x ULN or </= 5 x ULN if related to disease.

6) Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days and must agree to practice acceptable contraceptive methods. Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential.

7) Cardiac ejection fraction >/= 40% (by either cardiac echo or MUGA scan). Documentation of recent (</= 6 months from screening) outside reports is acceptable.
Exclusion Criteria:1) Breast feeding females

2) Patients with active infections (viral, bacterial, and fungal are not eligible).

3) Patients with active secondary malignancy will not be eligible.
.
Links
Registration Number: NCT01289457
Study Information on Clinical Trials Registry (clinicaltrials.gov)
Other Links:
.
Results

Return to Clinical Trials at M.D. Anderson Cancer Center